A monthly injection for managing severe asthma could help patients safely reduce or even discontinue daily steroid ...
Apogee Therapeutics, Inc. (NASDAQ: APGE) on Tuesday shared interim data from the Phase 1b trial of zumilokibart (APG777) in patients with mild-to-moderate asthma. The data covers 19 adult patients ...
An asthma treatment that only requires patients to have two jabs a year to prevent life-threatening attacks will be available in Britain. The pharmaceutical giant GSK has been granted marketing ...
Hosted on MSN
Life-saving asthma drug taken twice a year slashes hospital admissions by three-quarters
A twice-yearly injection that could prevent thousands of asthma patients from suffering life-threatening attacks will go on sale in Britain within months. Trials show the ‘ultra-long-acting’ drug, ...
The sizzle is the excitement about the hunt for the next big blockbuster, and the only one that anyone sees on the horizon is ...
The American College of Pulmonologists has published new clinical guidelines for the use of biological therapy in severe ...
A 45-year-old woman presents with long-standing exertional dyspnea, wheezing, and intermittent dry cough, which has been ongoing for over the past 10 years.
Osteoarthritis is listed as the most common type of arthritis in the UK, as stated by the NHS. This condition causes joints to become painful and stiff. While symptoms vary, many people resort to ...
GSK plc agreed to buy Rapt Therapeutics, a US-based biotech developing treatments for patients with inflammatory and ...
Apogee Therapeutics (APGE) leverages IL-13 pathway optimization to enable less frequent dosing, targeting a leadership shift ...
More than 10 million people in the UK live with arthritis and many take medication to ease pain, but the NHS warns certain people should seek medical advice before taking them ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results